REGEN
ToolsNotesBlogFAQ
← The board35/100 reports · early signal
Community read · grade S · Regulatory approval

Retatrutide

An investigational triple GIP/GLP-1/glucagon receptor agonist producing some of the…

Built from 35 anonymous reports · a pattern, not a conclusion

The read

What people observed

Every report answers on a 1–5 scale. This is the whole distribution, never an average pretending to be one number, though the average is beside it.

n=35
1 · no effect
4
2 · barely
7
3 · modest
5
4 · clearly worked
11
5 · textbook
8
3.3/5
Average reported outcome
74%
Would run it again
35
Reports filed · early signal

What it did, and what else showed up

Counts across this compound's reports, never an average. One report can select several answers.

Reported positive outcomes

cognition
8
appetite suppression
6
better bloodwork
5
fat loss
4
faster recovery
4
joint / tendon relief
4
skin / hair
4
mood / focus
4
strength / pump
4
better sleep
3
libido
3
cardiovascular / circulation
3
injury healing
2
more energy
1

Reported side effects

Kept separate from positive outcomes on purpose.

none / clean
8
mood / anxiety
7
fatigue
6
injection-site irritation
5
heart rate
5
sleep disruption
4
appetite change
4
GI / nausea
2
headache
2

How it was run

What people brought it in for, and how long they stayed on it. Intent, not a result or a treatment claim.

What people were researching

appetite / weight
4
skin / hair
3
joint / tendon comfort
2
focus / cognition
2
libido / sexual function
2
recovery / injury
1
sleep
1
mood / anxiety
1
body composition
1
immune / inflammation
1
cardiovascular / blood pressure
1
longevity / healthspan
1

How long they ran it

1 wk
9
2 wk
3
4 wk
7
6 wk
4
8 wk
3
12 wk
6
16 wk+
3
Safety

Anecdote, never medical advice.

These are anonymous personal reports on an experimental research compound, not clinical evidence, and they never set the grade. Talk to a licensed clinician before you start, stop, or change a dose.

Put the whole protocol
in one place.